Abstract
People throughout the world have used hallucinogenic drugs in religious ceremonies for thousands of years. Native American Church members use peyote, a cactus plant that contains mescaline, believing that it allows them to communicate easily with God. In a similar fashion, native populations of Mexico use mushrooms that contain psilocybin in their religious rites. In 1986, 12 percent of high school seniors had tried a hallucinogenic drug, and about 4 percent had used a hallucinogen in the past month. The illicit hallucinogens are classified by the DEA as Schedule I drugs.1–3
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
O’Brien, R., and S. Cohen. The Encyclopedia of Drug Abuse. Facts on File, New York, 1984.
Schonberg, S. K. (Ed.). Specific drugs. In Substance Abuse: A Guide for Health Professionals. American Academy of Pediatrics, Elk Grove Village, Illinois, 1988, pp. 115–182.
Johnston, L. D., P. M. O’Malley, and J. M. Bachman. Drug use in high school seniors: The class of 1986. U.S. Department of Health and Human Services publication number (ADM)87–1535. Rockville, Maryland, 1987.
Wilford, B. B. (Ed.). Major drugs of abuse. In Drug Abuse: A Guide for the Primary Care Physician. American Medical Association, Chicago, 1981, pp. 21–84.
Jaffe, J. H. Drug addiction and drug abuse. In Goodman and Gilman’s The Pharmacological Basis of Therapeutics. Ed. by A. G. Gilman, L. S. Goodman, T. W. Rail, and F. Murad. Macmillan, New York, 1985, pp. 532–581.
Strassman, R. J. Adverse reaction to psychedelic drugs: A review of the literature. Journal of Nervous & Mental Disease, 172:572–578, 1984.
Beck, J. E., and D. V. Gordon. Psilocybin mushrooms.> Pharm. Chem. Newsletter, 4:1–4, 1982.
Schwartz, R. H., and D. E. Smith. Hallucinogenic mushrooms. Clinical Pediatrics, 27:70–73, 1988.
Schwartz, R. H. Mescaline: A survey. American Family Physician, 37:122–124, 1988.
Clinko, R. P., H. Roehtich, D. R. Sweeney, et al. Ecstasy: A review of MDMA and MDA. International Journal of Psychiatry Medicine, 16:359–372, 1987.
Dawling, D. G., E. T. McDonough III, and R. O. Bost. Eve and ecstasy: A report of five deaths associated with MDEA and MDMA. Journal of the American Medical Association, 257:1615–1617, 1987.
Seymour, M. A., D. Smith, D. Inaba, and M. Landry. MDMA. In New Drugs: Look- Alikes, Drugs of Deception, and Designer Drugs. Hazelden, Center City, Minnesota, 1989, pp. 117–132.
Barnes, D. M. New data intensify the agony over ecstasy. Science, 239:864–866, 1988.
Brown, R. T., and N. J. Braden. Hallucinogens. Pediatric Clinics of North America, 34:341–347, 1987.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag New York Inc.
About this chapter
Cite this chapter
Milhorn, H.T. (1990). Hallucinogens. In: Chemical Dependence. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-3418-0_16
Download citation
DOI: https://doi.org/10.1007/978-1-4612-3418-0_16
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-8004-0
Online ISBN: 978-1-4612-3418-0
eBook Packages: Springer Book Archive